287 related articles for article (PubMed ID: 34272171)
1. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
[TBL] [Abstract][Full Text] [Related]
2. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Chifotides HT; Masarova L; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
[TBL] [Abstract][Full Text] [Related]
3. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
[TBL] [Abstract][Full Text] [Related]
4. Management of myelofibrosis after ruxolitinib failure.
Bose P; Verstovsek S
Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
6. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
7. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
8. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
Mascarenhas JO; Verstovsek S
Cancer; 2022 Jul; 128(14):2717-2727. PubMed ID: 35385124
[TBL] [Abstract][Full Text] [Related]
9. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
Bose P; Mesa RA
Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
[TBL] [Abstract][Full Text] [Related]
10. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian JJ; Vannucchi AM; Verstovsek S; Colak G; Dey D; Harrison C
Blood Adv; 2023 Sep; 7(18):5421-5432. PubMed ID: 37530627
[TBL] [Abstract][Full Text] [Related]
11. Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
[TBL] [Abstract][Full Text] [Related]
12. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
13. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
14. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
16. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.
Bose P
Expert Opin Orphan Drugs; 2019; 7(10):415-425. PubMed ID: 33094033
[TBL] [Abstract][Full Text] [Related]
17. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
18. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
19. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
20. Recent progress of JAK inhibitors for hematological disorders.
Kirito K
Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
